Stem Cell Joint Injections
What Is a Stem Cell Joint Injection?
A stem cell joint injection is the delivery of a cell-containing preparation into or around a joint in order to influence pain and function. The phrase is an umbrella label rather than the name of one standardized product. Preparations sold or described under this heading differ in their source tissue, in how they are processed and in what they actually contain. Because of that, the specific preparation being proposed matters more than the general term, and the wider biological treatments overview explains where these injections sit among other options.
Which Preparations Are Grouped Under This Name?
Several distinct products are commonly described with the same wording, even though they are not interchangeable. Patients should ask which one is being planned and why.
- Bone marrow aspirate concentrate (BMAC): marrow drawn from the patient, concentrated and injected during the same session. It is a mixture of cells, platelets and plasma rather than a purified stem cell product.
- Adipose-derived preparations: cells obtained from the patient’s own fat tissue by mechanical or enzymatic processing. Composition varies widely with the technique used.
- Culture-expanded cells: cells grown in a laboratory before use. These are regulated differently from same-day preparations in most jurisdictions.
- Donor-derived or perinatal products: material obtained from amniotic tissue, umbilical cord or placenta. Claims about live stem cell content in these products are frequently not supported by independent testing.
Which Joint Problems Are They Used For?
In orthopaedic practice these injections are most often discussed for symptomatic osteoarthritis, for localized cartilage lesions and for some persistent tendon or ligament problems that have not settled with structured non-surgical care. The knee is by far the most studied joint, which is why the dedicated page on stem cell treatment for the knee covers that evidence separately. Use in the hip, shoulder and ankle is supported by far less data, and results from one joint should not be assumed to transfer to another.
Who May Be a Candidate, and Who Is Not?
A cellular injection is not routine care and is not a first-line treatment. It is considered only after a confirmed diagnosis and after standard measures have been given a fair trial. Suitability depends on the joint involved, the degree of cartilage loss, mechanical symptoms such as locking or giving way, limb alignment, body weight and general health.
An injection is generally not appropriate where there is active joint or skin infection, an untreated bleeding disorder, an active malignancy under treatment, or advanced end-stage arthritis with bone-on-bone contact and deformity. In that last group a timely joint replacement assessment usually offers more reliable relief, and delaying it in favour of repeated injections can waste time and money.
Assessment Before the Procedure
The decision rests on examination rather than on imaging alone. History clarifies the pattern, duration and triggers of pain; examination assesses range of motion, swelling, stability, alignment and gait. Weight-bearing radiographs show joint space, alignment and osteophytes, while MRI may be added when cartilage, meniscal or tendon detail changes the plan. Where an inflammatory or infective cause is possible, blood tests and joint aspiration take priority over any biological injection, because injecting an inflamed or infected joint is unsafe. The overview of joint cartilage treatment describes how these findings guide the choice between options.
How Bone Marrow Is Collected and Processed
When a bone marrow preparation is selected, the sequence is usually as follows. Each step is carried out under sterile conditions.
- The skin over the pelvis is cleaned and anaesthetised, and the harvest site is identified.
- Marrow is aspirated through a needle placed into the iliac crest, often from more than one position to improve cell yield.
- The aspirate is centrifuged in a closed processing system to separate the cellular fraction from red cells and excess plasma.
- The concentrate is injected into the target joint, in many cases with ultrasound or fluoroscopic guidance to confirm needle position.
The number and type of cells obtained vary between patients and between systems, and no same-day device produces a defined, guaranteed dose. Patients are entitled to ask what will be collected, how it will be processed and what will be injected.
Anaesthesia, Setting and Duration
Most same-day cellular injections are performed with local anaesthesia, sometimes with light sedation when marrow is harvested. The procedure is normally carried out as a day case, and the combined harvest, processing and injection commonly takes about one to two hours depending on the system used. Patients usually walk out the same day, although driving immediately afterwards is not advised when sedation has been given or when the lower limb has been injected.
The First Days Afterwards
Soreness at the harvest site and a temporary increase in joint pain or stiffness in the first days are common and usually settle. Ice, simple analgesia and relative rest are typically sufficient. Anti-inflammatory medication is sometimes restricted for a short period around a biological injection, but practice varies, so the instruction given by the treating surgeon should be followed rather than a general rule found online. Heavy loading, running and impact activity are avoided in the early phase.
Rehabilitation and Return to Activity
An injection is not a stand-alone treatment. Whatever preparation is used, the functional result depends on the rehabilitation that follows it. A structured programme normally restores range of motion first, then addresses quadriceps, hip abductor or rotator cuff strength according to the joint involved, and finally reintroduces loading and sport-specific work. A personalised programme is planned for each patient, and gradual progression matters more than a fixed calendar, because response times differ considerably between individuals.
What the Current Evidence Supports
Published studies are heterogeneous: preparations, doses, control treatments and outcome measures differ, and many trials are small. Some report short- to medium-term improvement in pain and function in knee osteoarthritis, while others show no advantage over placebo or over established injections. There is no reliable evidence that a cellular injection regrows normal hyaline cartilage, reverses established arthritis or dependably prevents joint replacement. Major rheumatology and orthopaedic bodies have not recommended these injections as routine care, and any consensus favouring them is limited to selected cases. Established alternatives such as PRP injection therapy have their own separate evidence base and should be discussed on their own terms.
Risks and Complications
The risks are those of an injection plus, where marrow is taken, those of the harvest. They include pain and bruising, bleeding or haematoma, joint or skin infection, a temporary inflammatory flare, and injury to nearby nerves or vessels. Harvest-site pain at the pelvis can persist for some days. Donor-derived products carry additional concerns about transmissible disease and about processing that the patient cannot verify. Autologous and donor-derived preparations should therefore not be presented as equivalent, and cost should never be the only comparison made between them.
Alternatives Worth Comparing
Before agreeing to a cellular injection it is reasonable to review what else is available for the same problem: weight management and activity modification, a supervised strengthening programme, analgesia, corticosteroid or hyaluronic acid injection, bracing or orthoses, and — in the right circumstances — cartilage surgery, osteotomy or joint replacement. The pages on knee osteoarthritis treatment and orthopaedic stem cell therapy set out how these options are weighed against each other. Cost, the absence of insurance cover for many biological injections and the strength of the evidence all belong in that conversation.
When to Seek Medical Advice
Urgent assessment is needed for increasing redness or drainage at the injection or harvest site, worsening swelling or pain, persistent fever, new numbness or weakness, a change in limb colour, breathing difficulty or any allergic reaction. A joint that becomes suddenly hot, red and swollen requires assessment before any planned biological procedure. For an individual assessment of whether such an injection is appropriate, you can arrange a consultation through the contact page.